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Abstract
Lewy bodies and Lewy neurites constitute the cardinal neuropathological features of both
Parkinson's disease (PD) and Lewy body dementia (LBD). Whereas α-synuclein has been found to
be the major component of the Lewy body, the mechanisms by which neurons degenerate, as well
as basic mechanisms involved in the formation of α-synuclein-related inclusions, remain obscure.
We have suggested previously that potential mechanisms are likely to leave a "molecular signature"
or protein adduct within the Lewy body, and have found examples of such signatures in previous
studies. In this study, we demonstrate increased FOXO3 in association with Lewy bodies and Lewy
neurites in LBD and PD brain tissue. Since FOXO proteins are involved in several pathways
responsible for the regulation of cell death, cell proliferation, and cell metabolism, the ectopic
localization of FOXO3 to Lewy bodies provides evidence that aberrations in basic cellular
biochemistry may contribute to inclusion formation, which is likely more complex than a simple
"gain of function" toxicity as is commonly opined. In light of the known interaction of FOXO3 and
14-3-3, basic protein-protein interaction between these proteins and α-synuclein may be key.
Background
Parkinson's disease (PD) is the second most common age-
related neurodegenerative disease after Alzheimer's dis-
ease (AD) [1,2]. Like many other neurodegenerative dis-
eases, PD and Lewy body dementia (LBD) are increasingly
recognized as disorders of protein aggregation and inclu-
sion body formation [3]; in particular, PD is defined by
the presence of Lewy bodies and Lewy neurites [4,5]. Cor-
tical Lewy bodies also constitute the defining neuropatho-
logical characteristics of LBD, a common form of
dementia that exists in a "pure" form or overlaps with AD
neuropathology [4]. α-Synuclein is the major component
of the Lewy body in PD and LBD [6] and is currently used
as a diagnostic marker of Lewy bodies. Mutations in α-
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synuclein are also described in a subset of familial PD kin-
dreds, whereas aggregated α-synuclein occurs in both
familial and sporadic PD lesions [7]. Besides α-synuclein,
many molecules such as 14-3-3 protein and ubiquitin
have been found in Lewy bodies [8-10]. It is also sug-
gested that 14-3-3 protein which shares amino acid
sequence homology with α-synuclein may be associated
with Lewy body formation [8].
It is generally accepted that progressive, irreversible and
regionally specific neurodegeneration, with Lewy bodies
and Lewy neurites are the essential pathological hallmarks
of idiopathic PD. The precise etiology, however, is
unclear. One of the leading hypotheses suggests that oxi-
dative stress and generation of reactive oxygen species
damages macromolecules, resulting ultimately in cell
death [11]. In fact, Lewy bodies themselves have been
shown to contain adducts induced by oxidative stress
[12].
The forkhead box transcription factor, class O (FOXO) is
the mammalian homologue of DAF-16, which is known
to regulate life span of Caenorhabditis elegans [13,14]. In
mammals, the FOXO class of transcription factors are key
players in the regulation of cell-fate decisions, such as cell
death, cell proliferation, and cell metabolism [15]. It has
been reported that phosphorylation/dephosphorylation
of FOXO protein, which results in the translocation
between cytoplasm and nucleus, is a major regulatory
mechanism of FOXO-dependent-transcription [16]. A
recent study indicated that three FOXO family members
including FOXO1, FOXO3, and FOXO4 play essential
roles in the response to physiologic oxidative stress in
hematopoietic stem cells of experimental mice [17]. In the
present study, we examined the expression of FOXO3a




Hippocampal tissue with adjacent temporal cortex from
patients with "pure" LBD (n = 3, ages 68–78 years), LBD
plus AD pathology (AD/LBD) (n = 4, ages 59–84 years),
brainstem from PD cases (n = 4, ages 53–108 years), and
age-matched controls (n = 3, ages 66–86 years) with sim-
ilar postmortem intervals (LBD, AD/LBD and PD: 4–15 h;
controls: 6.25–22 h), were fixed either in formalin or in
methacarn (methanol:chloroform:acetic acid; 60:30:10)
at 4°C overnight. Following fixation, tissue was dehy-
drated through ascending ethanol, embedded in paraffin,
and 6-μm sections placed on silane-coated slides.
Immunohistochemistry
Immunohistochemistry was performed by the peroxidase
anti-peroxidase protocol essentially as described previ-
ously [18,19]. All slides were randomized and blinded
with regards to age and disease status prior to immunohis-
tochemical staining and subsequent analysis. Briefly,
slides were immersed in xylene, hydrated through graded
ethanol solutions, and endogenous peroxidase activity
eliminated by incubation in 3% hydrogen peroxide for 30
min. To reduce non-specific binding, sections were incu-
bated for 30 min in 10% normal goat serum in Tris-buff-
ered saline (TBS; 50 mM Tris-HCl, 150 mM NaCl, pH
7.6). After rinsing briefly with 1% normal goat serum in
TBS, the sections were incubated overnight at 4°C with
either rabbit polyclonal antibody to FKHRL1 (FOXO3a)
(1:100) [20], mouse monoclonal antibody to α-synuclein
(1:100; Abcam, Cambridge, MA) or rabbit polyclonal
antibody to 14-3-3 β (1:100; Santa Cruz Biotechnology,
Santa Cruz, CA). Sections were sequentially thereafter
incubated with either goat anti-rabbit or goat anti-mouse
antisera (ICN, Costa Mesa, CA) followed by species-spe-
cific peroxidase anti-peroxidase antibody (ICN, Costa
Mesa, CA). Antibodies were localized using 3-3'-diami-
nobenzidine as a chromogen (Dako Corp, Carpinteria,
CA). In some cases, antigen retrieval using Biocare Medi-
cal decloaking chamber was applied before the incubation
of the primary antibody.
Results
The cellular localization of FOXO3a was examined in the
hippocampus of LBD, AD/LBD, and age-matched control
patients by immunohistochemical techniques using an
antibody to FOXO3a. Whereas immunoreactivity of
FOXO3a localized to the cytoplasm similarly in hippoc-
ampal neurons in control cases (Fig. 1A) as well as in cases
of LBD (Fig. 1B), FOXO3a strongly and specifically local-
ized to cortical Lewy bodies in all cases of pure LBD (Fig.
1C) and AD/LBD (Fig. 1D, case of age 64). Lewy neurites
also contained FOXO3a in LBD and AD/LBD (Fig. 1E).
Immunostaining these same cases for 14-3-3 protein also
revealed specific localization in cortical Lewy bodies (Fig.
1F, case of age 59).
The significant overlap between the immunoreactivity to
α-synuclein and FOXO3a further confirms the specific
localization of FOXO3a in cortical Lewy bodies as well as
in classical Lewy bodies in the brainstem of cases with PD
(Fig. 2). Most Lewy bodies were found to be positive for
α-synuclein and FOXO3a on adjacent serial sections, indi-
cating the presence of FOXO3a in Lewy bodies in PD
brain.
Discussion
The localization of FOXO3a to Lewy bodies and Lewy
neurites in PD and LBD indicates that FOXO3a is a poten-
tial component of Lewy bodies. While Lewy bodies are
known also to be comprised of α-synuclein and ubiquitin
[21] and occur in a variety of clinical disease states [7,22-Molecular Neurodegeneration 2009, 4:32 http://www.molecularneurodegeneration.com/content/4/1/32
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24], the mechanism of α-synuclein accumulation in the
Lewy body and its role in disease is poorly understood [7].
The finding of FOXO3a in intimate association with PD/
LBD lesions suggests that LB and Lewy neurite formation
encompasses more basic cellular pathophysiology than
simple "gain of function" toxicity. Given the role of FOXO
in such processes as phosphorylation, acetylation/
deacetylation, ubiquitination, and protein-protein inter-
actions [25], the potential of multiple hits cannot be dis-
counted [26,27]. In fact, FOXO3a has been shown to
trigger the death of motoneurons in mice with the trans-
location from cytoplasm to nucleus [28], and a recent
study also showed oxidative stress induces neuronal
necrosis by activating FOXO3 [29].
Interestingly, however, several lines of evidence now indi-
cate that α-synuclein accumulation is fundamentally pro-
tective [30,31]. In our own studies, α-synuclein
aggregation occurs in concert with microtubule polymeri-
zation and that an aggregate, once formed, is cytoprotec-
tive response against noxious stimuli [32,33]. This is
compatible with the once controversial concept that neu-
rodegenerative disease lesions are markers of pathogenic
disease response rather than indicators of etiology [34,35]
Oxidative stress is believed to be an important factor in
cell death induction and considerable evidence has accu-
mulated that oxidative stress is involved in the pathogen-
esis of PD and α-synuclein aggregation [36-38]. As a
transcription factor, it is necessary for FOXO3a to locate in
nucleus to play its cell death-inducing role. In the present
study, the high level expression of FOXO3a protein in an
inclusion body in the neuronal cytoplasm suggests that
FOXO3a may not reach the nucleus (e.g., to affect its
known function in the apoptotic pathway). This finding
adds further evidence to the notion that Lewy bodies may
protect affected neurons from death and furthers the
notion that profound alterations in cytoplasmic-nuclear
trafficking are a key element of the neurodegenerative
process [39,40]. The finding of the specific isoform
FOXO3a in neurodegenerative disease as presented in this
work, as well as its role in attenuating amyloid-like
pathology in mouse models [41], clearly supports the
investigation of the other members of the FOXO family
transcription factor in aging and disease.
14-3-3 is a family of dimeric proteins that can modulate
interaction between proteins and they are involved in cell
signaling, regulation of cell cycle progression, intracellular
trafficking/targeting, cytoskeletal structure and transcrip-
tion [42,43]. In previous studies, phosphorylated
FOXO3a has been shown to bind to 14-3-3 protein, caus-
ing cytoplasmic retention of phosphorylated FOXO3 and
inhibition of FOXO3-induced transcriptional activation
[16]. Interestingly, 14-3-3 protein has also been localized
to Lewy bodies [8]. Therefore, while the mechanism of
accumulation of FOXO3a in Lewy bodies awaits further
study, a direct interaction between FOXO3a and 14-3-3
protein remains a distinct possibility. Since α-synuclein
In hippocampal neurons, FOXO3a is present at similar levels  in control (A), and cases diagnosed with LBD (B) Figure 1
In hippocampal neurons, FOXO3a is present at simi-
lar levels in control (A), and cases diagnosed with 
LBD (B). Cortical Lewy bodies, however, exhibit intense 
immunolabeling for FOXO3a, in cortical regions from all 
cases diagnosed with pure LBD (C), and with AD/LBD (D). 
Lewy neurites also accumulate FOXO3a (E). Significantly, 
cortical Lewy bodies also demonstrate increased 14-3-3 (F). 




Adjacent serial sections of brainstem of a case of PD immu- nostained for FOXO3a (A) and α-synuclein (B) Figure 2
Adjacent serial sections of brainstem of a case of PD 
immunostained for FOXO3a (A) and α-synuclein (B). 
Co-localization of FOXO3a and α-synuclein in classical Lewy 
bodies (arrows) was observed. *Landmark vessel. Scale bars 
= 20 μm.Molecular Neurodegeneration 2009, 4:32 http://www.molecularneurodegeneration.com/content/4/1/32
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shares physical and functional homology with 14-3-3 pro-
teins [44], it is reasonable to speculate that FOXO3a, α-
synuclein, and 14-3-3 protein may form a complex, pre-
venting the dephosphorylation and translocation of
FOXO3a, and promote cell survival. This potential pro-
tein interaction is the subject of ongoing studies in our
laboratory.
Conclusion
Our study demonstrates the localization of FOXO3a pro-
tein to Lewy bodies and Lewy neurites, suggesting a role of
FOXO3a in the morphogenesis of inclusions in synuclei-
nopathies. Given the pleiotrophic effects of FOXO3a in
cellular pathophysiology, our results further the increas-
ingly important concept that inclusion formation is a
complex process, favoring an adaptive disease response
over a primary deleterious process. Further studies inves-
tigating direct protein interaction in vitro and in vivo are in
progress.
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